Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Triple acting antimicrobials that are refractory to resistance development

Triple acting antimicrobials that are refractory to resistance development

US Patent 8481289 · Granted Jul 9, 2013

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Thermophile peptidoglycan hydrolase fusion proteins and uses thereof2022
Characterization of four prophage endolysins specific for clostridium perfringen2020
Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB—Sa2018
Phage twort endolysin CHAP domain is lytic for Staphylococcus aureus2017
Isolated recombinant cDNA2017
Staphylococcal Phage2638A endolysin amidase domain is lytic for Staphylococcus a2015
Peptidoglycan hydrolase antimicrobials for eradicating lactobacilli that contami2015
Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB—Sa2015
Staphylococcus haemolyticus prophage φSH2 endolysin is lytic for Staphylococcus 2015
Bacteriophage lytic enzymes as alternative antimicrobials2015
Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin2014
Lys K endolysin is synergistic with lysostaphin against MRSA2013